Print this page
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer: A Phase I/II Feasibility Study.
Primary Objective:
1. To assess acute toxicity of moderately hypofractionated MR-guided adaptive pelvic IMRT using the Common Terminology Criteria for Adverse Events (CTCAE v6.0).
Secondary Objectives:
1. To report patient-reported outcomes using EORTC (European Organisation for Research and Treatment of Cancer) core questionnaire (QLQ-C30) with EN24 companion
2. To assess late toxicity of moderately hypofractionated MR-guided adaptive pelvic IMRT using the Common Terminology Criteria for Adverse Events (CTCAE v6.0).
3. To assess locoregional recurrence and disease-free survival.
4. To assess the feasibility and dosimetric advantages
Protocol Number:
152601
Phase:
Phase I/II
Applicable Disease Sites:
Corpus Uteri
Principal Investigator:
Lara Hathout
Scope:
Local
Participating Institutions:
- RWJBarnabas Health
- Cooperman Barnabas, Livingston
- Rutgers University
For further information about clinical trials, please contact us at 732-235-7356.